Anders Ingvarsson (CEO) LifeAssays today May, 2015
Om LifeAssays Anders Norling, Chairman of the Board in LifeAssays LifeAssays is a unique Swedish company focused on veterinary diagnostic products. Based on its in-house developed and patented technology, the company develop, produce, market and sell instruments and consumables to veterinary clinics in the Nordic area, most of Europe and has recently taken the step on to the US market. LifeAssays test for acute phase proteins in dogs (canine CRP) has been the entry ticket to a fast growing and profitable market, veterinary diagnostics. To the canine test the company added similar products for cat and horse recently. The robust and very simple test system LifeAssays supplies makes it possible to test high performing horses patient side before competing, a way to make sure that only healthy horses compete. says Anders Norling, chairman of the board in LifeAssays 2
LifeAssays strategically placed in IDEON Science park Company founded 2000 Located in Lund, IDEON Science Park Public company, listed on NGM in Stockholm All Development, Production, Market and Sales done at HQ in Lund 3
LifeAssays unique system for near patient testing Magneto Immuno Assays LifeAssays IPR Strong IP Rights on process and technology Platform for Near Patient Testing in Veterinary- and Human medicine Focus on Veterinary diagnostics and Acute Phase Proteins Instrument and disposable test reagents for Dog, Cat and Horse. The method/instrument Pat.no: US 6, 110, 660 Procedure for quantitative and qualitative determination of chemical substances, based on molecular recognition and measurement of magnetic permeability. Pat.no: US 7, 910, 063 B2 Drift compensated magnetic permeability detector Pat.no: US 2011, 0104659 A1 Device for biochemical processing and analysis of sample The sampling device Pat.no: US 6, 319, 209 B1 Disposable test vial with sample delivery device for dispensing sample into reagent Pat.no: US 2010/0255460 A1 Device for biochemical processing and analysis of a sample The one-chip computer Pat.no: US 2009/0061418 A1 Disposable analytical microprocessor device 4
LifeAssays applications in veterinary medicine strategic focus for the Company since 2011 Global veterinary diagnostic market expected to reach 4 200 million USD by 2018 Advanced treatments now drives market towards near patient testing USA the largest market & Asia Pacific fastest growing Spending on healthcare for pets 53.300 musd in 2011. LifeAssays shall focus the application of its patented technology for POC testing on the veterinary market in general and the pet segment in particular. 5
LifeAssays transfers advanced diagnostics from the central service laboratory Sample taken and sent to external laboratory for analysis Veterinary Clinic Answer back to Veterinarian within 24 to 72 hours. Test laboratory 6
to the local veterinary clinic LifeAssays test gives the veterinarian a result within 15 minutes Veterinary Clinic 7
Advanced testing in a PoCT setting LifeAssays products are true PoCT Magnetic measurement: Robust and reliable: No calibration needed. Species specific antibodies, Very specific without any interference. (otherwise very common in methods using Light All calibrations already on the supplied chip in the testkit. All software updates immediately implemented through the one chip computer 8
LifeAssays Veterinary one instrument for multiple parameters 9
LifeAssays 2014 growth in more than sales Sales increased more than 60% in SEK Instruments up more than 300% Reagents up 28% in numbers Broadened product portfolio Expansion of the Distributor network First steps to increase the production capacity for reagents and instruments Agreement with Chinese company on Human diagnostics Key evaluations of all three products set up and monitored 10
LifeAssays product portfolio new Products and improved quality to drive sales New instrument will be launched Q2 2015. User- and production improvements Consumables (reagents) for Dog Cat Horse Colour coded regent tubes 11
LifeAssays have expanded it s network of Distributors now present on major markets markets 40 % Sweden: 300 clinics Today: 40% of all clinics USA: 40 000 clinics Target: 20% of all clinics Europe: 30 000 clinics Target: 25% of all clinics Japan: 10 000 clinics Target: 70% of all clinics 12
LifeAssays on the largest market for veterinary diagnostics, USA all ground work done Innovative Veterinary solutions, IVS Direct sales Marketing Support to Henry Schein Henry Schein, IVS Partner 150 sales reps and 3 call centres trained during Q1 Vendor of the week in April Special focus on Equine Q2 40 000 clinics 20% LifeAssays target market 70 000 000 dogs and 85 000 000 cats 844 000 Race horses 44% of the total Veterinary diagnostic market 520 million USD today to 780 million USD in 2018 68% of all house holds have a pet Total spending on pets 53 billion USD in 2012 13
LifeAssays distributor in the US IVS anticipates increasing sales after Henry Schein training Since the first of the year, IVS has been highly dedicated to the training of Henry Schein sales representatives. The Lexington facility, as well as the Ocala, FL facility, have a large interest in horse racing. The recent Vendor of the Week offered exposure to the inside sales reps, visiting field reps and veterinarians and interest in equine haptoglobin was generated. Continued focus on training and communication with Henry Schein will be the focus throughout the year. Marketing strategies are underway to utilize special programs and offerings extended by Henry Schein. Additionally, IVS has been in discussions with a prominent equine veterinarian and is grooming him to be a key opinion leader in the field Karen L Moody, President at Innovative Veterinary Solutions 14
LifeAssays established in Europe Nordic markets the engine in LifeAssays sales Nordic countries Alere general distributor Direct sales in Sweden for all LifeAssays products Europe ex. Nordic markets Present in 3 of 5 major market and evaluating channels in UK. Nordic countries plus Balkan, Austria and Poland 30 000 clinics 25% LifeAssays target market 50 000 000 dogs and 55 000 000 cats Horse racing important 30% of the total Veterinary diagnostic market 520 million USD today to 780 million USD in 2018 15
LifeAssays in Asia/Pacific the fastest growing markets India, China and South-East Asia, the largest growth potential in veterinary diagnostics APAC 523 million USD today - 911 million USD in 2018 Companion animals 214 today - 401 million USD in 2018 APAC 18% of the veterinary diagnostics market Japan 45% China 26% India 20% JAPAN 10 500 clinics 2/3 LifeAssays target market 13 000 000 dogs and 8 000 000 cats 9% of the total Veterinary diagnostic market 251 million USD today to 409 million USD in 2018 Distributor since January 2015 Registration on-going, all documents submitted May 12 for registration of dog AND cat test Launch plan ready, seminars starting at Swedish Embassy September 10 16
Issuing of new shares and 2015
LifeAssays Unitemission - Erbjudandet Emissionen är med företräde för existerande aktieägare Fulltecknad emission tillför bolaget 15 MSEK före emissionskostnader vilka beräknas till c:a 700 tkr. Vid fullt utnyttjande av de TO som ingår kan bolaget tillföras ytterligare c:a 5 MSEK Företrädesrätten gäller Varje aktie ger rät att teckna en (1) Unit En (1) Unit består av tre (3) aktier) och en (1) Teckningsoption En (1) TO ger rätt att teckna en (1) aktie Teckningskurs 0,15 Kr eller 0,05 Kr/aktie Avstämningsdag 20 maj Teckningstid 22 maj till och med 5 juni 18
LifeAssays Unitemission Vad skall den användas till? 2015 är det år vi ägnar uteslutande åt försäljning Utvecklingsavdelningen Avslutar instrumentutvecklingen Marknadsstudier till stöd för försäljningsavdelningen Marknads och försäljningsavdelningen Lansering i Japan Seminarieverksamhet Kundutbildning med svenska veterinärer Lansering i Kina Kundutbildning med svenska veterinärer Marknadsföringsverktyg USA Satsning på Hästmarknaden Geografiskt fokus Europa Fortsätta förstärka nätverket av distributörer, främst UK och Tyskland Norden Ökat engagemang direkt i marknaden 19
LifeAssays 2015 the year of Sales First quarter sales up 50% in SEK Vs. Q1, 2014 37 new instruments sold and placed Vs. 21 Q1, 2014 Sales of Reagents up 51% in number of tests sold Second quarter Finalising the registration in Japan Focus on Equine market in US Scale up of production of new instrument Launch in China 20
That s all